Diseño de antagonistas no peptídicos del receptor AT1 de la angiotensina II basado en docking molecular
Fecha
Autores
Autor corporativo
Título de la revista
ISSN de la revista
Título del volumen
Editor
Compartir
Altmetric
Resumen
The pharmaceutical industry and the development of drugs does not exist in our country due to the high economic investment that it requires. This is why the idea was put forward to develop a rational drug design using virtual and free tools such as molecular docking, predictive mathematical models of toxicological properties and virtual screening to design 155 chemical molecules tested against the AT1 receptor of angiotensin. II (a protein associated with increased blood pressure). Three molecules were obtained with a potential antagonism of the AT1 receptor of angiotensin II and promising toxicological properties that are expected to be 3 new active ingredients in the future for the treatment and control of arterial hypertension in the world, a disease that according to 2016 figures from the World Health Organization suffer from 1 in 3 people in the world.